Literature DB >> 26558714

Cerebal overinhibition could be the basis for the high prevalence of epilepsy in persons with Down syndrome.

Bruno Henrique Silva Araujo1, Laila Brito Torres2, Laura Maria F F Guilhoto3.   

Abstract

Down syndrome (DS) is the most common cause of genetic intellectual disability, and the trisomy 21 is associated with more than 80 clinical traits, including higher risk for epilepsy. Several hypotheses have been put forward to explain the mechanisms underlying increased seizure susceptibility in DS: inherent structural brain abnormalities, abnormal cortical lamination, disruption of normal dendritic morphology, and underdeveloped synaptic profiles. A deficiency or loss of GABA inhibition is hypothesized to be one of the main alterations related to the epileptogenic process. Paradoxically, enhanced GABA inhibition has also been reported to promote seizures. One major functional abnormality observed in the brains of individuals and mouse models with DS appears to be an imbalance between excitatory and inhibitory neurotransmission, with excessive inhibitory brain function. This review discusses the GABAergic system in the human DS brain and the possible implication of the GABAergic network circuit in the epileptogenic process in individuals where the pathogenetic basis for epilepsy is unknown.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Down syndrome; Epilepsy; GABA; Infantile spasms; LOMEDS

Mesh:

Substances:

Year:  2015        PMID: 26558714     DOI: 10.1016/j.yebeh.2015.10.004

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  6 in total

1.  Long-term effects of maternal choline supplementation on CA1 pyramidal neuron gene expression in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease.

Authors:  Melissa J Alldred; Helen M Chao; Sang Han Lee; Judah Beilin; Brian E Powers; Eva Petkova; Barbara J Strupp; Stephen D Ginsberg
Journal:  FASEB J       Date:  2019-06-10       Impact factor: 5.191

2.  Down Syndrome iPSC-Derived Astrocytes Impair Neuronal Synaptogenesis and the mTOR Pathway In Vitro.

Authors:  Bruno H S Araujo; Carolini Kaid; Janaina S De Souza; Sérgio Gomes da Silva; Ernesto Goulart; Luiz C J Caires; Camila M Musso; Laila B Torres; Adriano Ferrasa; Roberto Herai; Mayana Zatz; Oswaldo K Okamoto; Esper A Cavalheiro
Journal:  Mol Neurobiol       Date:  2017-11-11       Impact factor: 5.590

Review 3.  Dementia in Down syndrome: unique insights for Alzheimer disease research.

Authors:  Ira T Lott; Elizabeth Head
Journal:  Nat Rev Neurol       Date:  2019-03       Impact factor: 42.937

4.  Engineered microRNA-based regulatory element permits safe high-dose miniMECP2 gene therapy in Rett mice.

Authors:  Sarah E Sinnett; Emily Boyle; Christopher Lyons; Steven J Gray
Journal:  Brain       Date:  2021-11-29       Impact factor: 13.501

5.  Treatment of Epilepsy Associated with Common Chromosomal Developmental Diseases.

Authors:  Magdalena Budisteanu; Claudia Jurca; Sorina Mihaela Papuc; Ina Focsa; Dan Riga; Sorin Riga; Alexandru Jurca; Aurora Arghir
Journal:  Open Life Sci       Date:  2020-02-28       Impact factor: 0.938

Review 6.  Personalized Medicine Using Cutting Edge Technologies for Genetic Epilepsies.

Authors:  Sheila Garcia-Rosa; Bianca de Freitas Brenha; Vinicius Felipe da Rocha; Ernesto Goulart; Bruno Henrique Silva Araujo
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.